Subacute sclerosing panencephalitis (SSPE) is a progressive disease of the central nervous system that usually occurs against the background of a previous measles infection. It is characterized by a long and slow development of neurological symptoms, such as changes in behavior, cognitive impairment, seizures, and loss of movement. The pathology is caused by an infection with the measles virus, which leads to irreversible changes in neuronal cells and brain structure. Diagnosis of the disease is often based on clinical manifestations, anamnesis, and imaging methods, as well as laboratory tests aimed at detecting antibodies to the measles virus. Studying this disease is important, as it poses a threat to the health of children and young people, allowing us to better understand the mechanisms of inflammatory and degenerative processes in the neurosystem.
History of the disease and interesting historical facts
Subacute sclerosing panencephalitis was first described in the early 20th century, when physicians began to notice a link between previous measles infections and the development of neurological disorders. In 1930, German pathologist Sigmund Freud noted cases of the disease in children during measles epidemics, which prompted further research into the disease. By the 1960s, the first studies substantiating a link between measles infection and the development of SSPE had been conducted. Understanding of the pathophysiology of this disease was greatly improved by the discovery of immunofluorescence techniques that can detect antibodies to the measles virus in brain tissue.
Epidemiology
Statistics on the incidence of subacute sclerosing panencephalitis vary by region, but it is known that the disease occurs mainly in children and adolescents who have had measles. According to global studies, the incidence ranges from 4 to 11 cases per 100,000 children, especially in countries where measles vaccination is insufficient. SSPE often develops 7-10 years after measles infection, making it a rare but serious complication that requires the attention of the medical community.
Genetic predisposition to this disease
Genetic predisposition to subacute sclerosing panencephalitis is currently the subject of active research. It has been established that certain genetic markers may increase the risk of the disease, but the exact mechanisms of interaction between the measles virus and genetic predisposition are not fully understood. The main attention is drawn to genes associated with the immune response, such as HLA class II. Studying polymorphisms in these genes may help in identifying risk groups for SSPE.
Risk factors for the development of this disease
Risk factors that contribute to the development of subacute sclerosing panencephalitis include:
- Age (more common in children and adolescents);
- Postponed measles;
- Immunodeficiencies that may affect the body's response to the virus;
- Lack of measles vaccination;
- History of neurological diseases.
These factors highlight the importance of vaccination in the prevention of both measles and its possible complications, including PE.
Diagnosis of this disease
Diagnosis of subacute sclerosing panencephalitis includes several stages:
- Main symptoms: changes in personality traits, memory impairment, convulsions, motor disorders, which can lead to complete disability;
- Laboratory tests: analysis of cerebrospinal fluid for the presence of antibodies to the measles virus;
- Radiological examinations: magnetic resonance imaging (MRI) showing brain atrophy and other changes;
- Other types of diagnostics: electroencephalography to assess the electrical activity of the brain;
- Differential diagnosis: exclusive diagnosis with other inflammatory, infectious or degenerative diseases of the brain.
Treatment
Treatment of subacute sclerosing panencephalitis is multifaceted and includes:
- General treatment: supportive therapy aimed at improving quality of life;
- Pharmacological treatment: use of antiviral drugs, corticosteroids to reduce the inflammatory response;
- Surgical treatment: possible in the presence of pronounced neurological changes;
- Other types of treatment: speech therapy and rehabilitation therapy to restore lost functions.
List of medications used to treat this disease
Among the main drugs used in the treatment of PSP are:
- Acyclovir;
- Corticosteroids (prednisolone);
- Immunoglobulins;
- Drugs that improve brain metabolism (mexidol, memantine).
Disease monitoring
Monitoring of the condition of patients with subacute sclerosing panencephalitis includes regular examinations and monitoring of neurological functions:
- Control stages: annual neuropsychological tests, assessment of the dynamics of neurological symptoms;
- Prognosis: depends on the time of treatment initiation and individual characteristics of the patient;
- Complications: May range from severe disability to death.
Age-related features of the disease
Subacute sclerosing panencephalitis usually occurs in children and young adults, but symptoms and the rate of progression of the disease may vary depending on age:
- In children: often has an acute onset and rapid progression;
- In adolescents: it may proceed more mildly, but also leads to serious consequences;
- In adults: cases are less common and are often associated with weakened immunity or concomitant diseases.
Questions and Answers
- What is subacute sclerosing panencephalitis? It is a progressive neurological disease that develops after measles infection, resulting in changes in neuronal cells.
- What are the main symptoms of PSP? Symptoms include behavioral changes, memory impairment, seizures, and motor impairment.
- How is the disease diagnosed? Diagnosis includes clinical manifestations, laboratory tests, MRI and differential diagnosis.
- What treatment is used for PSP? Treatment includes antiviral drugs, corticosteroids and rehabilitation measures.
- What is the prognosis for patients with PSP? The prognosis depends on the timeliness of treatment and individual characteristics, but serious complications are possible.
